Abstract
Metabolic reprograming contributes to esophageal tumorigenesis. A better understanding of how esophageal cancer (EC) cells reactivate primitive signaling to retain glucose metabolism under unfavorable conditions is essential for the development of therapeutic interventions to treat EC. Current achievements in the field of EC glucose metabolism have been critically reviewed to address several fundamental questions. These include: 1) the association of abnormal glucose metabolism and EC risk; 2) alterations of genes and/or proteins that contribute to glucose oncometabolism in EC; 3) signal transduction pathways that promote EC consumption of glucose; and, 4) targeting the glycolytic element or the EC dependency on excessive glucose consumption to prevent growth of EC caused by different genomic changes.
Keywords: Tumor metabolism, glycolysis, mitochondria, altered genes, inhibitors, glucose dependence.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Glucose Oncometabolism of Esophageal Cancer
Volume: 17 Issue: 3
Author(s): Jason S. Hochwald and Jianliang Zhang
Affiliation:
Keywords: Tumor metabolism, glycolysis, mitochondria, altered genes, inhibitors, glucose dependence.
Abstract: Metabolic reprograming contributes to esophageal tumorigenesis. A better understanding of how esophageal cancer (EC) cells reactivate primitive signaling to retain glucose metabolism under unfavorable conditions is essential for the development of therapeutic interventions to treat EC. Current achievements in the field of EC glucose metabolism have been critically reviewed to address several fundamental questions. These include: 1) the association of abnormal glucose metabolism and EC risk; 2) alterations of genes and/or proteins that contribute to glucose oncometabolism in EC; 3) signal transduction pathways that promote EC consumption of glucose; and, 4) targeting the glycolytic element or the EC dependency on excessive glucose consumption to prevent growth of EC caused by different genomic changes.
Export Options
About this article
Cite this article as:
Hochwald S. Jason and Zhang Jianliang, Glucose Oncometabolism of Esophageal Cancer, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (3) . https://dx.doi.org/10.2174/1871520616666160627092716
DOI https://dx.doi.org/10.2174/1871520616666160627092716 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Many Faces of Glutathione Transferase Pi
Current Molecular Medicine Multidisciplinary Cancer Therapy with Telomerase-Specific Oncolytic Adenovirus
Current Cancer Therapy Reviews In Vivo Roles of CDC25 Phosphatases: Biological Insight into the Anti-Cancer Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design Recent Developments in the Mechanism of Anticancer Agents Based on Electron Transfer, Reactive Oxygen Species and Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Deubiquitinating Enzyme Inhibitors and their Potential in Cancer Therapy
Current Cancer Drug Targets Protein Biomarkers in Cancers of the Digestive Tract - a Step Towards Personalized Medicine
Current Proteomics Molecular Interplay between Platelets and the Vascular Wall in Thrombosis and Hemostasis
Current Vascular Pharmacology Stage N2/IIIA Non Small Cell Lung Cancer: An Evidence-Based Review
Current Cancer Therapy Reviews Tea (Camellia sinensis (L.)): A Putative Anticancer Agent in Bladder Carcinoma?
Anti-Cancer Agents in Medicinal Chemistry Head and Neck Cancer Treatments through Chemotherapy to Magnetic Systems: Perspectives and Challenges
Current Radiopharmaceuticals Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion
Current Drug Targets Functional Poly(ε-caprolactone) Based Materials: Preparation, Self-assembly and Application in Drug Delivery
Current Topics in Medicinal Chemistry The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer
Current Clinical Pharmacology Azacitidine, as a DNMT Inhibitor Decreases hTERT Gene Expression and Telomerase Activity More Effective Compared with HDAC Inhibitor in Human Head and Neck Squamous Cell Carcinoma Cell Lines
Current Molecular Pharmacology Small Players With Big Roles: MicroRNAs as Targets to Inhibit Breast Cancer Progression
Current Drug Targets Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Vascular and Metabolic Actions of the Green Tea Polyphenol Epigallocatechin Gallate
Current Medicinal Chemistry Host Microbiomes in Tumor Precision Medicine: How far are we?
Current Medicinal Chemistry Vitamin D and Cancer Stem Cells in the Gastrointestinal Tract
Current Medicinal Chemistry